Anavex Life Sciences Corp (AVXL)

[TTTav66]

Here's a brief, related, editorial from Howard Fillet and Yuko Hara of the Alzheimer's Drug Discovery Foundation from July, with a mention of blarcamesine as one of 3 therapies in phase 3 trials targeting synaptic plasticity or neuroprotection: https://link.springer.com/article/10.14283/jpad.2022.64?fbclid=IwAR1gl4xJKYOdoNsfN_e9gP8TZ5ZSD3GQfii4b0NHbUtd-qio9k2DLCVCqBs

At an Alzheimer’s conference (Alzheimer’s Disease Therapeutics: Alternatives to Amyloid) that I attended in late 2018, Dr. Fillet introduced Dr. Missling prior to the presentations, and made special note of the fact that Anavex was classified under synaptic disfunction, but that Dr. Missling would speak to the fact that 2-73 "probably does a lot more than that". It was also interesting to learn from Dr. Missling that it was Dr. Fillet who first introduced him to Dr. Abraham Fisher, inventor of Anavex 3-71, which lead to Anavex licensing that compound in 2014.